CD19 and neoplasm: The mice with established tumors (tumor size >50 mm3) were treated twice by intravenous injections of CD19-CAR T cells; the CD19-4D5scFv or CD19-his fusion protein was injected at day 9, day 15, and day 18 (each 200 μg per mouse).